Cytek Biosciences (CTKB) reported $201M in revenue for fiscal 2025, +0.5% year on year. That ranks #2659 by revenue among 2853 SEC filers and #515 in Technology. It posted a net loss of −$66.5M for the same year. Revenue has grown 16.8% a year on average since 2020 ($92.8M then). The fiscal 2025 balance sheet shows $462M in total assets and $90.9M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $201M | +0.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $104M | −6.0% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$40.4M | −$19.9M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$66.5M | −$60.5M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$4.7M | −$30.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.1M | +15.9% | FY20252025-12-31 |
| Total assetsAssets | $462M | −7.6% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $342M | −13.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $90.9M | −8.0% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $44.1M | −$18.9M | Open → |
| Q2 20262026-06-30 | $48.1M | −$12.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Cytek Biosciences, Inc.
- Ticker
- CTKB
- Exchange
- Nasdaq
- SIC classification
- Laboratory Analytical Instruments (3826)
- Fiscal year end
- 12-31
- CIK
- 0001831915
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| I3 VerticalsIIIV | $213M | $17.9M |
| JanelJANL | $207M | $5.7M |
| Energy VaultNRGV | $204M | −$104M |
| Cytek BiosciencesCTKB | $201M | −$66.5M |
| Cbak Energy TechnologyCBAT | $195M | −$9.4M |
| UltralifeULBI | $191M | −$5.9M |
| Cass Information SystemsCASS | $191M | $35.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Cytek Biosciences — Key figures |url=https://companiesranked.com/en/company/cytek-biosciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Cytek Biosciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/cytek-biosciencesBibTeX
@misc{companiesranked-en-company-cytek-biosciences-2026,
author = {{CompaniesRanked}},
title = {{Cytek Biosciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/cytek-biosciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-012352 · February 26, 2026
{{cite web |title=Cytek Biosciences — Key figures — 10-K (0001628280-26-012352) |url=https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.